NATIONAL BUREAU OF ECONOMIC RESEARCH
NATIONAL BUREAU OF ECONOMIC RESEARCH

Regulation of the Pharmaceutical-Biotechnology Industry

Patricia M. Danzon, Eric L. Keuffel


This chapter is a preliminary draft unless otherwise noted. It may not have been subjected to the formal review process of the NBER. This page will be updated as the chapter is revised.

Chapter in forthcoming NBER book Economic Regulation and Its Reform: What Have We Learned?, Nancy L. Rose, editor
Conference held September 9-10, 2005
Forthcoming from University of Chicago Press

download in pdf format
   (3771 K)

email paper

This paper is available as PDF (3771 K) or via email.

This paper was revised on January 16, 2013

Acknowledgments

Machine-readable bibliographic record - MARC, RIS, BibTeX

Users who downloaded this chapter also downloaded these:
Cockburn Is the Pharmaceutical Industry in a Productivity Crisis?
Branstetter, Chatterjee, and Higgins w17188 Regulation and Welfare: Evidence from Paragraph IV Generic Entry in the Pharmaceutical Industry
Danzon, Mulcahy, and Towse w17174 Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition and Procurement
Danzon and Furukawa w17226 Cross-National Evidence on Generic Pharmaceuticals: Pharmacy vs. Physician-Driven Markets
Rose Learning from the Past: Insights for the Regulation of Economic Activity
 
Publications
Activities
Meetings
Data
People
About

Support
National Bureau of Economic Research, 1050 Massachusetts Ave., Cambridge, MA 02138; 617-868-3900; email: info@nber.org

Contact Us